HER2-targeting therapies, like trastuzumab and lapatinib, are not typically used in CRC treatments, however these treatments have been investigated for use with CRC [19, 20], and results from breast cancer studies regarding the L755S alteration may be validated in CRC to help develop treatment regimens. Here, ERBB2 is linked to breast cancer.